乙酰肝素酶在卵巢癌组织中的表达及其临床意义

Expression of heparanase in ovarian cancer and its clinical significance

目的 探讨乙酰肝素酶在卵巢癌组织中的表达及其与患者年龄、临床病理特征及预后的关系。方法 采用免疫组化S-P法检测41例卵巢癌组织及10例正常卵巢组织中乙酰肝素酶蛋白的表达，并结合卵巢癌的组织类型、分化程度、临床分期及预后进行分析。结果①乙酰肝素酶蛋白在卵巢癌组织中的阳性表达率为80．48％，在正常卵巢组织中为10．00％（P＜0．05）。②临床Ⅲ～Ⅳ期卵巢癌中乙酰肝素酶蛋白的表达高于Ⅰ～Ⅱ期（P＜0．01）；低分化程度的卵巢癌中乙酰肝素酶蛋白的表达高于高-中分化者（P＜0．05）。③各组织类型卵巢癌中乙酰肝素酶蛋白的表达无显著性差异（P＞0．05）。结论 乙酰肝素酶在卵巢癌发展过程中起重要作用，检测乙酰肝素酶蛋白的表达有望成为判断卵巢癌预后的标志。

Objective To examine the relationship of heparanase expression and age, clinicopathological features and prognosis of ovarian cancer patients. Methods Forty-one ovarian cancer specimens, from the patients admitted to the 3 hospitals of our university during the period of Jan 2003 to Nov 2005, were of serous carcinoma （22 cases） and mucous carcinoma （ 10 cases） and other types （9 cases）, of which 16 were well and moderately differentiated and 25 poorly differentiated. Ten specimens of normal ovarian tissues were taken as normal controls. The heparanase expression was detected in all specimens and its relationship with histologic type, differentiation, FIGO stage and prognosis of the ovarian cancer was analyzed. Results The positive rate of heparanase expression was 80.48% in ovarian cancer tissues and 10.00% in normal ovarian tissues （P 〈 0.05 ）. The heparanase expression was significantly higher in FIGO stage Ⅲ and Ⅳ than in Ⅰ and Ⅱ , and was significantly higher in poorly differentiated ovarian cancer tissues than in moderately and well-differentiated tissues. There was no significant difference in heparanase expression among ovarian cancer tissues of various histologic types. Conclusion Heparanase plays a crucial role in the carcinogenesis of ovarian cancer and it may be used as a marker for prognosis in future.